Association of complications of type 1 and type 2 diabetes mellitus with glycaemic regulation parameters obtained from continuous glucose monitoring systems (continuous glucose monitoring, CGM)

HR  EN   

Project acronym: CGM-DIACOMP

Project number: 581-UNIOS-81

Principal investigator: Full Professor Ines Bilić-Ćurčić
Funding source: European Union – NextGeneration EU
Project duration: 1 October 2025. to 30 September 2029.
Budget: 106.600,00 EUR

Project summary:
Type 1 and type 2 diabetes mellitus represent major public health challenges worldwide, as long-term inadequate glycaemic control leads to the development of serious vascular and cardiac complications. The introduction of continuous glucose monitoring (CGM) systems has enabled more precise and dynamic assessment of glycaemic control, providing novel metrics that go beyond traditional laboratory parameters.The CGM-DIACOMP project investigates the association between CGM-derived glycaemic regulation parameters and the development of microvascular and macrovascular complications in patients with type 1 and type 2 diabetes mellitus. In patients with type 1 diabetes, the project focuses on the relationship between functional and structural changes of blood vessels and microcirculation and CGM parameters. In patients with type 2 diabetes, the association between glycaemic regulation, myocardial deformation assessed by advanced echocardiographic techniques (2D strain), and biomarkers of heart failure will be evaluated. A key focus of the project is endothelial dysfunction and oxidative stress as central mechanisms in the pathogenesis of diabetic complications. It is hypothesised that poorer CGM-derived glycaemic control is associated with more pronounced vascular impairment and subclinical myocardial dysfunction. The project integrates modern laboratory methods, non-invasive vascular and cardiac assessments, and digital data analysis, combining clinical, biochemical, and CGM data. The expected results will contribute to a better understanding of the early relationship between disturbances in glycaemic regulation and target organ damage, supporting the development of more personalised approaches to monitoring and treatment of patients with diabetes mellitus. The project has strong scientific, clinical, and public health relevance and contributes to the advancement of digital and translational medicine.